Jesal Haribhakti discusses the recent advancements in the management of age-related macular degeneration (AMD), focusing on new treatment interventions and innovations. These include newer anti-VEGF intravitreal injections and the development of intravitreal therapies for slowing geographic atrophy. These advancements have allowed for an enhanced level of care for patients with AMD. Haribhakti also emphasizes the importance of identifying specific OCT prognostic biomarkers to ensure at-risk patients have appropriate follow-up and early disease progression identification. This is significant because it allows for more targeted and frequent monitoring, compared to previous general guidelines. Haribhakti has no relevant financial disclosures.
Source link
Six biomarkers predict AMD progression with greater certainty than ‘large drusen’ sign
